Our Corporate Sponsors
Corporate sponsors assist the National Fragile X Foundation by supporting our current programs and new initiatives across all strategic initiatives — advocacy, education, treatment, and research.
Our Corporate Sponsors
Corporate sponsors assist the National Fragile X Foundation by supporting our current programs and new initiatives across all strategic initiatives — advocacy, education, treatment, and research.
Meet Our 2024 Sponsors
Harmony Biosciences
Harmony Biosciences specializes in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that when empathy and innovation meet, a better life can begin for people living with neurological diseases. Zynerba Pharmaceuticals is now part of Harmony Biosciences which expands Harmony’s pipeline with a product candidate that could address rare neuropsychiatric disorders including Fragile X syndrome.
Tetra Therapeutics
Tetra Therapeutics, a Shionogi Group Company, is focused on developing treatments for central nervous system diseases and disorders with a lead program in Fragile X syndrome (FXS). Shionogi acquired Tetra in 2020 as part of its mission to develop medications for unmet medical needs and to contribute meaningfully to society. Shionogi and Tetra are researching an investigational treatment called zatolmilast for FXS. The U.S. Food & Drug Administration has granted zatolmilast Orphan Drug Designation, Rare Pediatric Disease Designation and Fast Track Designation. If approved, zatolmilast could offer people living with FXS the first cognitive treatment developed specifically for them. Learn about their research and find out more about the eligibility criteria to join their study here.
Kaerus Bioscience
Kaerus is developing targeted therapeutics that address an underlying ion channel dysfunction in Fragile X syndrome that contributes to hyper-excitability of the central nervous system in these patients. Our unique mechanistic approach to targeting BK channels has enabled Kaerus to expand focus on other rare genetic syndromes linked to the KCNMA1 gene.
Sponsor Benefits
Interested in learning more about our Corporate Sponsorship program?
If you have questions, we’d love to hear from you! You can reach out to Kristin Bogart directly, or submit your question or comment through our contact form.
Kristin Bogart,
Senior Director, Development and Communications
kristin@fragilex.org
202-747-6209